Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07061574 · ClinicalTrials.gov registry record · Phase 1
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
A Phase 1 study of Type 1 Diabetes and New Onset, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 11
- Study locations
NCT07061574 is a Phase 1 study of Type 1 Diabetes and New Onset that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 120 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (85% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT07061574, a Phase 1 study of Type 1 Diabetes and New Onset, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 11
- Study locations
Study Summary
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.
Conditions Studied
Interventions
- DRUG Adalimumab
- DRUG Anti-thymocyte globulin (ATG)
- DRUG verapamil extended-release capsule
Study Locations (11)
Florida
- University of Florida - Gainesville
- University of Miami - Miami
California
- UCSF - San Francisco
Colorado
- Barbara Davis Center for Diabetes University of Colorado Anschutz - Aurora
Connecticut
- Yale University - New Haven
Indiana
- Indiana University - Indianapolis
Minnesota
- University of Minnesota - Minneapolis
New York
- University of Buffalo - Buffalo
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-03-30 |
| Est. Completion | 2031-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07061574
The ClinicalTrials.gov registry entry for NCT07061574 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (85% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Adalimumab is the first listed.
NCT07061574 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT07061574 about?
NCT07061574 is a clinical study titled "A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes". This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.
What is the current status of trial NCT07061574?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2026-03-30. Estimated completion is 2031-04-15.
What conditions does trial NCT07061574 study?
This clinical trial studies the following conditions: Type 1 Diabetes, New Onset.
What interventions are being tested in trial NCT07061574?
The interventions under investigation include: Adalimumab (DRUG), Anti-thymocyte globulin (ATG) (DRUG), verapamil extended-release capsule (DRUG).
Who is sponsoring clinical trial NCT07061574?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07061574 being conducted?
This trial has 11 study locations across California, Colorado, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Denosumab for Type 1 Diabetes
RECRUITING · Phase 1
-
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
RECRUITING · Phase 1
-
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
RECRUITING · Phase 1
-
A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.